Protagenic Therapeutics shareholders approve all five proposals at 2024 annual meeting

Protagenic Therapeutics, Inc.new

Elected Garo H. Armen and Brian J. Corvese as Class III directors with ~1.87M and ~1.85M for votes.
Approved repricing of outstanding stock options: 1,803,833 for, 184,143 against, 70,373 abstain.
Ratified MaloneBailey LLP as auditor for FY2024: 3,492,771 for, 81,987 against, 72,564 abstain.
Approved issuance of common stock warrant shares from Oct 2024 agreements: 1,928,277 for, 58,942 against.
Approved amendment to 2016 Equity Plan allowing option repricing without shareholder approval: 1,803,817 for.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.